AtriCure (NASDAQ:ATRC – Get Free Report) and SNDL (NASDAQ:SNDL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
Valuation and Earnings
This table compares AtriCure and SNDL”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AtriCure | $534.53 million | 2.71 | -$11.45 million | ($0.24) | -121.13 |
| SNDL | $677.32 million | 0.52 | -$11.29 million | ($0.04) | -34.00 |
Insider & Institutional Ownership
99.1% of AtriCure shares are owned by institutional investors. 3.5% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
AtriCure has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, SNDL has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Profitability
This table compares AtriCure and SNDL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AtriCure | -2.14% | -1.15% | -0.88% |
| SNDL | -1.64% | -1.42% | -1.18% |
Analyst Recommendations
This is a breakdown of recent ratings for AtriCure and SNDL, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AtriCure | 1 | 3 | 6 | 1 | 2.64 |
| SNDL | 1 | 0 | 1 | 0 | 2.00 |
AtriCure presently has a consensus target price of $48.43, indicating a potential upside of 66.59%. SNDL has a consensus target price of $5.00, indicating a potential upside of 267.65%. Given SNDL’s higher possible upside, analysts clearly believe SNDL is more favorable than AtriCure.
Summary
AtriCure beats SNDL on 9 of the 15 factors compared between the two stocks.
About AtriCure
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
About SNDL
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
